MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI's 2026 Performance [Yahoo! Finance]
Krystal Biotech, Inc. (KRYS)
Last krystal biotech, inc. earnings: 11/4 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.krystalbio.com/investors
Company Research
Source: Yahoo! Finance
FDA staffing cuts that could slow the regulatory approval pipeline that biotech valuations depend on. Moderna (MRNA) is the largest position at 2.3% weight and expects phase 3 norovirus and melanoma data in 2026 after rallying 82% year to date; Krystal Biotech (KRYS) posted $204 million in net income for 2025 with VYJUVEK revenue growing 34% year over year and has phase 3 readouts due before year-end; Sarepta Therapeutics (SRPT) is recovering from ELEVIDYS revenue falling 33% in Q4 2025 but expects a return to profitability in 2026; Recursion Pharmaceuticals (RXRX) is down 23% year to date amid dilution concerns from a $300 million equity offering. FDA operational capacity under new leadership will determine whether XBI's one-year momentum sustains, with consistent regulatory approval timelines required to avoid simultaneous valuation compression across all 150+ holdings due to the equal-weight structure that amplifies both gains and losses. Have You read The New Report Shaking Up
Show less
Read more
Impact Snapshot
Event Time:
KRYS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KRYS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KRYS alerts
High impacting Krystal Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
KRYS
News
- Assessing Krystal Biotech (KRYS) Valuation After Recent Share Price Weakness [Yahoo! Finance]Yahoo! Finance
- Krystal Biotech (KRYS) is now covered by Wolfe Research. They set a "peer perform" rating on the stock.MarketBeat
- Krystal Biotech (KRYS) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "buy (b-)" to "hold (c+)".MarketBeat
- Updated YJUVEK Label and KB803 Progress Could Be A Game Changer For Krystal Biotech (KRYS) [Yahoo! Finance]Yahoo! Finance
- Epidermolysis Bullosa Market Set for Significant Upswing During the Forecast Period (2025-2034) Amid Rising Therapeutic Advancements | DelveInsight [Yahoo! Finance]Yahoo! Finance
KRYS
Earnings
- 2/17/26 - Beat
KRYS
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/6/26 - Form 3
- 3/6/26 - Form 3
- KRYS's page on the SEC website